Binder Hagit 4

What Happened
Hagit Binder, General Manager of NeuroSense Therapeutics Ltd. (NRSN), received an award/ grant of 200,000 restricted ordinary shares on March 26, 2026. The shares were issued at a $0.00 price (award), so the reported acquisition value is $0. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction type/code: Award/Grant (A) — 200,000 restricted shares
• Transaction date: March 26, 2026; Form 4 filed March 30, 2026 (timely filing)
• Price: $0.00 per share; reported acquisition value $0
• Vesting: shares vest in equal quarterly installments over two years starting March 26, 2026, subject to continued service (see footnote)
• Trustee: shares are to be registered in the name of a trustee to qualify for Israeli Section 102 tax benefits (footnote)
• Shares owned after transaction: not specified in the provided filing details

Context
This is a standard restricted-share compensation grant to an executive; it is neither a market purchase (which some investors view as a bullish signal) nor a sale. The grant is subject to a two-year quarterly vesting schedule and trustee registration for Israeli tax treatment, meaning the recipient must remain employed to realize the full award.